You are here: Industry Insights > AbbVie

News List

AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE pharmaphorum
December 19, 2018
NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for a kind of leukaemia.
Lilly's Taltz beats out AbbVie's megadrug Humira in psoriatic arthritis showdown fiercepharma
December 19, 2018
What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis (PsA).
AbbVie streamlines management team to 4 executives under CEO Gonzalez fiercepharma
December 19, 2018
AbbVie has been on a hot streak lately thanks to the performance of its bestselling Humira, but as the company looks to the future, it has decided to streamline its management team.
AbbVie licences BioArctic’s Parkinson’s disease portfolio pharmaceutical-technology
December 18, 2018
Swedish biopharma company BioArctic has secured clearance from US Federal Trade Commission (FTC) to out-licence its alpha-synuclein antibody portfolio to AbbVie......
Executive Moves: AbbVie contractpharma
December 18, 2018
AbbVie has made changes to its Executive Leadership Team as part of an effort to streamline its organizational structure and support its growth strategy. The following will report to AbbVie chairman and chief executive officer Richard A. Gonzalez.
AbbVie, Roche eye first-line use of Venclexta in leukaemia pharmaphorum
December 17, 2018
AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena......
AbbVie suffers fresh setback with lung cancer drug Rova-T pharmaphorum
December 10, 2018
AbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer trial suggested that patients were living longer when treated with standard therapy.
AbbVie halts phase III TAHOE trial of Rova-T for SCLC pharmaceutical-technology
December 10, 2018
Following advice from an independent data monitoring committee, biopharma company AbbVie has ceased enrolment in its TAHOE trial evaluating Rovalpituzumab Tesirine.....
AbbVie halts late-stage TAHOE study of Rova-T in small-cell lung cancer firstwordpharma
December 06, 2018
AbbVie on Wednesday announced that it was stopping enrolment of the Phase III TAHOE study assessing rovalpituzumab tesirine, also known as Rova-T, as a second-line treatment for patients with advanced small-cell lung cancer.
Pfizer reaches a global agreement with AbbVie worldpharmanews
December 06, 2018
Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page